CHI’s 2nd Annual Preclinical Development

Venue: San Francisco,

Location: San Francisco,, California, United States

Event Date/Time: Feb 22, 2006 End Date/Time: Feb 24, 2006
Report as Spam


The ability to accurately predict safety earlier the drug development process depends largely on the model that is chosen. Animal models of disease and knowledge of specific pathways provide a means of evaluating and progressing drug candidates. The pressure to accelerate drug discovery and development has increased, driven by technology advancement and strong competitive forces.
Numerous opportunities exist to implement innovative paradigms to optimize candidate progression from discovery to early clinical evaluation. Successful development of new translational biomarkers will enable the progression of candidates from preclinical to clinical, and provide a means of predicting success in humans.
Who should attend: Scientists, Senior Scientists, Heads, Directors, Senior Directors, Vice Presidents, Senior Vice Presidents, of Preclinical R&D, Preclinical Studies, Preclinical & Regulatory Affairs, Preclinical Discovery, Preclinical Laboratory, Preclinical Development, Preclinical Sciences, Preclinical Pharmacology & Toxicology, Preclinical Biostatistics, Preclinical Models, Preclinical Biology, and Preclinical Safety